August 30
11:00 am - 12:00 pm EDT

LOCAL TIME

Identify and quantify point mutations in circulating tumor DNA: The ddPCR approach

Circulating tumour DNA (ctDNA) is tumour-deriver fragmented DNA which originates either directly from the tumour or from circulating tumour cells. Identifying and quantifying ctDNA in patient blood can aid in detecting, diagnosing, and monitoring a tumour or can guide and assess the efficacy of tumour-specific treatments.

Analysis remains challenging for this type of molecule because it requires high sensitivity and selectivity for target genes.

In this webinar, Dr. Kurt Sales, Chief Scientific Officer at Agilex Biolabs, will discuss analytical hurdles and platform compatibility with ctDNA detection and quantification. Illustrating the importance of platform choice in a bioanalytical approach, Dr. Sales will present a case study of our successful detection of exon 15 (V600E) of the B-Raf proto-oncogene (BRAF) using Digital Droplet PCR (ddPCR).

What will you learn?
  • How circulating tumour DNA (ctDNA) is being used to uncover insights in drug development
  • Current analytical challenges associated with ctDNA
  • Applying Droplet Digital PCR (ddPCR™) technology to detect ctDNA
Who should attend?
  • Industry professionals and scientists interested in gene therapy or advances in oncology research

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Kurt Sales

Kurt Sales

Chief Scientific Officer, Agilex Biolabs

Dr. Kurt Sales has over 25 years of experience in a career spanning research and development, early drug discovery, and regulated bioanalysis across preclinical and clinical drug development. At Agilex Biolabs, Kurt is Chief Scientific Officer, responsible for scientific integrity and strategic research and development.

Kurt has extensive expertise in pre-clinical and clinical assay development, cellular and molecular biology, molecular signaling, flow cytometry, cell-based models, and biomarkers, notably in the areas of inflammation and immunology. Widely published with 45 peer-reviewed scientific papers in high-impact journals, book chapters, and presentations at over 30 conferences, he also has extensive experience ensuring strict GLP compliance for bioanalytical assays and preclinical safety testing through PK/PD/Biomarker assays.

Kurt has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, a Bachelors of Science in Medicine with Honours in Pharmacology, and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organisation and Management and a Post Graduate Certificate in Management.

Arsalan Arif
moderator

Arsalan Arif

Founder & publisher, endpoints news

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.